Review: taking Fioricet and Robaxin together


Summary

Drug interactions are reported among people who take Fioricet and Robaxin together. This review analyzes the effectiveness and drug interactions between Fioricet and Robaxin. It is created by eHealthMe based on reports of 102 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Fioricet and Robaxin >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Fioricet

Fioricet has active ingredients of acetaminophen; butalbital; caffeine. It is often used in migraine. (latest outcomes from Fioricet 3,995 users)

Robaxin

Robaxin has active ingredients of methocarbamol. It is often used in muscle spasms. (latest outcomes from Robaxin 2,863 users)

On Jul, 28, 2016

102 people who take Fioricet, Robaxin are studied.


Number of reports submitted per year:

Fioricet and Robaxin drug interactions.

Drug effectiveness over time:

Fioricet:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 2 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 100.0% - (1 of 1 people)
  • not specified: 0.0% - (0 of 0 people)
Robaxin:
  • < 1 month: 0.0% - (0 of 2 people)
  • 1 - 6 months: 0.0% - (0 of 2 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 100.0% - (1 of 1 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Fioricet:
  • female: 66.0% - (2 of 3 people)
  • male: 50.0% - (1 of 2 people)
Robaxin:
  • female: 20.0% - (1 of 5 people)
  • male: 50.0% - (1 of 2 people)

Drug effectiveness by age:

Fioricet:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 100.0% - (1 of 1 people)
  • 50-59: 66.0% - (2 of 3 people)
  • 60+: 0.0% - (0 of 0 people)
Robaxin:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 2 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 0.0% - (0 of 1 people)
  • 50-59: 66.0% - (2 of 3 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

1 - 6 months:
  • anxiety and stress
  • migraine with aura
  • short-term memory loss
  • weight increased
not specified:
  • pain in extremity
  • hypertension
  • osteopenia
  • osteoporosis
  • pain
  • dizziness
  • fall
  • foot fracture
  • asthenia
  • mental disorder

Most common drug interactions by gender *:

female:
  • pain
  • foot fracture
  • mental disorder
  • pain in extremity
  • fall
  • osteopenia
  • osteoporosis
  • dizziness
  • hypertension
  • weight increased
male:
  • bronchitis
  • mental status changes
  • paraesthesia
  • renal failure acute
  • asthenia
  • dependence
  • diabetes mellitus
  • diabetes mellitus inadequate control
  • diabetic neuropathy
  • dizziness

Most common drug interactions by age *:

10-19:
  • deep vein thrombosis
  • pulmonary embolism
  • thrombosis
20-29:
  • cerebral thrombosis
  • deep vein thrombosis
  • headache
  • migraine with aura
  • pain
  • pulmonary embolism
  • short-term memory loss
  • weight increased
30-39:
  • palpitations
  • abdominal adhesions
  • impaired gastric emptying
  • injection site erythema
  • injection site haematoma
  • injection site haemorrhage
  • injection site pain
  • injection site urticaria
  • oedema lower limb
  • blood sodium increased
40-49:
  • pain
  • drug ineffective
  • abdominal pain
  • chest pain
  • constipation
  • dizziness
  • dyspnoea
  • fall
  • fatigue
  • insomnia
50-59:
  • pain
  • foot fracture
  • mental disorder
  • osteopenia
  • osteoporosis
  • pain in extremity
  • hypertension
  • dizziness
  • malaise
  • asthenia
60+:
  • bronchitis
  • mental status changes
  • nausea
  • paraesthesia
  • renal failure acute
  • arthralgia
  • asthenia
  • breast pain
  • discomfort
  • fall

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Fioricet and Robaxin?

Can you answer these questions?

More questions for: Fioricet, Robaxin

You may be interested in these reviews

More reviews for: Fioricet, Robaxin

On eHealthMe, Fioricet (acetaminophen; butalbital; caffeine) is often used to treat migraine. Robaxin (methocarbamol) is often used to treat muscle spasms. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.